405 related articles for article (PubMed ID: 15878382)
1. Testim 1% testosterone gel for the treatment of male hypogonadism.
Bouloux P
Clin Ther; 2005 Mar; 27(3):286-98. PubMed ID: 15878382
[TBL] [Abstract][Full Text] [Related]
2. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
[TBL] [Abstract][Full Text] [Related]
4. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function.
McNicholas TA; Dean JD; Mulder H; Carnegie C; Jones NA
BJU Int; 2003 Jan; 91(1):69-74. PubMed ID: 12614254
[TBL] [Abstract][Full Text] [Related]
5. Review of Testim gel.
McNicholas T; Ong T
Expert Opin Pharmacother; 2006 Mar; 7(4):477-84. PubMed ID: 16503819
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel.
Marbury T; Hamill E; Bachand R; Sebree T; Smith T
Biopharm Drug Dispos; 2003 Apr; 24(3):115-20. PubMed ID: 12673669
[TBL] [Abstract][Full Text] [Related]
7. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
Blick G; Khera M; Bhattacharya RK; Kushner H; Miner MM
Postgrad Med; 2013 Mar; 125(2):19-29. PubMed ID: 23816768
[TBL] [Abstract][Full Text] [Related]
8. 12-month observation of testosterone replacement effectiveness in a general population of men.
Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M
Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
[TBL] [Abstract][Full Text] [Related]
9. Absorption of testosterone gel 1% (Testim) from three different application sites.
Guay AT; Smith TM; Offutt LA
J Sex Med; 2009 Sep; 6(9):2601-10. PubMed ID: 19549089
[TBL] [Abstract][Full Text] [Related]
10. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.
Behre HM; Heinemann L; Morales A; Pexman-Fieth C
Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063
[TBL] [Abstract][Full Text] [Related]
11. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS).
Blick G; Khera M; Bhattacharya RK; Nguyen D; Kushner H; Miner MM
Pain Med; 2012 May; 13(5):688-98. PubMed ID: 22536837
[TBL] [Abstract][Full Text] [Related]
12. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men.
Meikle AW; Matthias D; Hoffman AR
BJU Int; 2004 Apr; 93(6):789-95. PubMed ID: 15049991
[TBL] [Abstract][Full Text] [Related]
13. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost.
Taylor F; Levine L
J Sex Med; 2010 Jan; 7(1 Pt 1):269-76. PubMed ID: 19694928
[TBL] [Abstract][Full Text] [Related]
14. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function.
Chiang HS; Hwang TI; Hsui YS; Lin YC; Chen HE; Chen GC; Liao CH
Int J Impot Res; 2007; 19(4):411-7. PubMed ID: 17538639
[TBL] [Abstract][Full Text] [Related]
15. Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents.
Seftel A
Int J Impot Res; 2007; 19(1):2-24. PubMed ID: 16193074
[TBL] [Abstract][Full Text] [Related]
16. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
[TBL] [Abstract][Full Text] [Related]
17. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.
Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ
Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499
[TBL] [Abstract][Full Text] [Related]
18. Testosterone supplementation: what and how to give.
Jockenhövel F
Aging Male; 2003 Sep; 6(3):200-6. PubMed ID: 14628500
[TBL] [Abstract][Full Text] [Related]
19. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.
Swerdloff RS; Wang C
Aging Male; 2003 Sep; 6(3):207-11. PubMed ID: 14628501
[TBL] [Abstract][Full Text] [Related]
20. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
